Improving treatments for Alzheimer's disease using SHIP1 inhibitors
Official title: Optimization of SHIP1 Inhibitors for the Treatment of Alzheimer's Disease
Funded at Indiana University Indianapolis · NIH-10941338 · Data updated 2026-11-12
This study is looking at new ways to help the brain clear out harmful substances linked to Alzheimer's disease by using special inhibitors that boost the brain's immune cells, which could lead to better treatments for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $2,217,438 |
| NIH project number | 1U01AG088021-01 |
| Project ID | NIH-10941338 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at high risk of developing the condition.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing and optimizing SHIP1 inhibitors to enhance the brain's ability to clear harmful beta-amyloid plaques associated with Alzheimer's disease. By targeting microglial cells, which are crucial for maintaining brain health and clearing neurotoxins, the study aims to improve the immune response in the brain. The approach involves understanding the genetic factors that influence microglial activity and how SHIP1 inhibitors can enhance this process. Patients may benefit from new therapeutic options that could slow down or prevent cognitive decline.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, potentially improving cognitive function and quality of life for patients.
How similar studies have gone: Previous research has shown promising results in targeting microglial activity for Alzheimer's treatment, suggesting that this approach could be effective.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Richardson, Timothy I — Indiana University Indianapolis
- Study coordinator: Richardson, Timothy I
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.